Geneva, April 28 -- International Clinical Trials Registry received information related to the study (NCT07537088) titled 'Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease' on April 12.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: First Affiliated Hospital of Wannan Medical College
Condition:
T2DM
CKD - Chronic Kidney Disease
Intervention:
Drug: Dulaglutide
Drug: SGLT2i
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: May 2026
Target Sample Size: 468
To know m...